Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

This publication has 15 references indexed in Scilit:

• Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
  Journal of Clinical Oncology, 2002
• Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
  British Journal of Dermatology, 2002
• ZD1839 (Iressa™) in Non-Small Cell Lung Cancer
  The Oncologist, 2002
• Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
  The Oncologist, 2002
• ZD1839 (Iressa™): For More Than Just Non-Small Cell Lung Cancer
  The Oncologist, 2002
• ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer
  Seminars in Oncology, 2002
• Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
  British Journal of Dermatology, 2001
• Epidermal growth factor-related peptides and their receptors in human malignancies
  Published by Elsevier ,2000
• The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents
  Drugs, 2000
• The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
  Pharmacology & Therapeutics, 1999